To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical Neisseria gonorrhoeae Isolates from Thailand and South Africa
Örebro University, School of Medical Sciences. Örebro University Hospital. WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine.
Centre for HIV & STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Bangrak STI Center, Bureau of AIDs TB and STIs, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Centre for HIV & STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Show others and affiliations
2019 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 63, no 12, article id e01479-19Article in journal (Refereed) Published
Abstract [en]

We evaluated the in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among recent consecutive clinical Neisseria gonorrhoeae isolates cultured in Thailand (n=99; 2018) and South Africa (n=100; 2015-2017). Zoliflodacin was highly active in vitro against all tested isolates (MIC range: 0.004-0.25; MIC50: 0.064, MIC90: 0.125 μg/ml), with no cross-resistance to any of the seven comparator antimicrobials. Our data support the initiation of the global zoliflodacin phase 3 randomized controlled clinical trial for uncomplicated gonorrhea.

Place, publisher, year, edition, pages
American Society for Microbiology , 2019. Vol. 63, no 12, article id e01479-19
Keywords [en]
South Africa, Thailand, gonorrhea, resistance, spiropyrimidinetrione, susceptibility, treatment, zoliflodacin
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-76830DOI: 10.1128/AAC.01479-19ISI: 000497999100028PubMedID: 31548184Scopus ID: 2-s2.0-85075554500OAI: oai:DiVA.org:oru-76830DiVA, id: diva2:1355559
Note

Funding Agencies:

Global Antibiotic Research and Development Partnership (Geneva, Switzerland)  

United Kingdom Department for International Development  

Dutch Ministry of Health, Welfare, and Sport  

South African Medical Research Council  

Federal Ministry of Education & Research (BMBF)

Available from: 2019-09-30 Created: 2019-09-30 Last updated: 2020-12-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Jacobsson, SusanneUnemo, Magnus

Search in DiVA

By author/editor
Jacobsson, SusanneUnemo, Magnus
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Antimicrobial Agents and Chemotherapy
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 51 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf